SCHEMBL8555

SCHEMBL8555

C1=NSc2ccccc2-c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.35
GPR84 Q9NQS5 4/20 0.32
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
BCHE P06276 1/20 0.30
POLB P06746 1/20 0.30
PTPRC P08575 1/20 0.30
MAPT P10636 1/20 0.30
THRB P10828 1/20 0.30
PKM P14618 1/20 0.30
IDO1 P14902 1/20 0.30
HPGD P15428 1/20 0.30
ALOX15 P16050 1/20 0.30
PTPN1 P18031 1/20 0.30
ACHE P22303 1/20 0.30
CES1 P23141 1/20 0.30
RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Urea SCHEMBL9162913 0.91 BCHE (0.37) TRPA1GPR84MEN1KMT2ALMNA
Carbamic Acid SCHEMBL4912038 0.89 BCHE (0.36) TRPA1MEN1KMT2AALDH1A1LMNA
SCHEMBL29039007 0.77 MEN1 (0.41) MEN1KMT2AALDH1A1PTPRCTHRB
SCHEMBL7849227 0.67 TRPA1 (0.33) TRPA1GPR84
SCHEMBL7845259 0.67 TRPA1 (0.33) TRPA1GPR84
SCHEMBL20145049 0.65 TRPA1 (0.39) TRPA1MEN1KMT2ABCHEPOLB
SCHEMBL1079397 0.64 TRPA1 (0.42) TRPA1
SCHEMBL3650633 0.64 TRPA1 (0.33) TRPA1
SCHEMBL563542 0.62 KDM4E (0.35) GPR84MEN1KMT2AKDM4EALDH1A1
SCHEMBL720559 0.61 ALDH1A1 (0.42) MEN1KMT2AKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
CN-119569763-A Light-emitting device, electronic apparatus, electronic device, and heterocyclic compound 三星显示有限公司 2025-03-07 CN claimed
CN-118955428-A Benzothiazinone vinylidene indene series compound with dibenzothiazepine octacycle system structure and preparation method thereof 浙大城市学院 2024-11-15 CN claimed
WO-2024206663-A1 REACTIVE CAPSID PROTEIN ASSOCIATED MOLECULES THE TRUSTEES OF INDIANA UNIVERSITY (US) 2024-10-03 WO claimed
CN-116854643-A Synthesis method of dibenzodiazepine or oxyazepine compound 中山大学 2023-10-10 CN claimed
CN-106187873-B A kind of aryl amine alkyl oxygen class compound and preparation method thereof 宜春学院 2019-11-05 CN claimed
US-20190125825-A1 SMALL-MOLECULE ADJUVANTS FOR ANTIBIOTICS TO ADDRESS ANTIBIOTIC RESISTANCE HIGH POINT UNIVERSITY 2019-05-02 US claimed
US-9974839-B2 Self-assembled toroidal-spiral particles and manufacture and uses thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2018-05-22 US claimed
CN-106187873-A A kind of aryl amine alkyl oxygen compounds and preparation method thereof 宜春学院 2016-12-07 CN claimed
CN-105085435-A Preparation method for crystalline dibenzothiazepine derivative Xuchang hengsheng pharmaceutical co ltd 2015-11-25 CN claimed
WO-2007050697-A2 COMPOSITIONS AND METHODS FOR THE ADMINISTRATION PSYCHOTROPIC DRUGS WHICH MODULATE BODY WEIGHT AZUR PHARMA III LIMITED (BM) 2007-05-03 WO claimed
US-20070093471-A1 Compositions and methods for the administration clozapine formulations which modulate body weight ALAMO PHARMACEUTICALS, LLC (US) 2007-04-26 US claimed
WO-2006081347-A2 CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT ELAN PHARMA INTERNATIONAL LIMITED (IE) 2006-08-03 WO claimed
US-20060173178-A1 Process for preparing dibenzothiazepine derivatives UBE INDUSTRIES, LTD. (JP) 2006-08-03 US claimed
US-7045621-B1 Process for producing dibenzothiazepine derivatives UBE INDUSTRIES, LTD. (JP) 2006-05-16 US claimed
EP-1347752-A4 ANTI-PROLIFERATIVE DRUGS UNIV RAMOT (IL) 2005-04-06 EP claimed
US-20040029860-A1 Anti-proliferative drugs RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2004-02-12 US claimed
EP-1347752-A2 ANTI-PROLIFERATIVE DRUGS Ramot at Tel-Aviv University Ltd. (IL) 2003-10-01 EP claimed
WO-2002043652-A2 ANTI-PROLIFERATIVE DRUGS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2002-06-06 WO claimed
EP-1201663-A1 PROCESS FOR PRODUCING DIBENZOTHIAZEPINE DERIVATIVES Ube Industries, Ltd. (JP) 2002-05-02 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173178-A1 Process for preparing dibenzothiazepine derivatives TPMT, BBOX1, NISCH TRPA1 1688/4885GPR84 4529/4885MEN1 4480/4885
US-20190125825-A1 SMALL-MOLECULE ADJUVANTS FOR ANTIBIOTICS TO ADDRESS ANTIBIOTIC RESISTANCE MYD88, TLR5, TLR3 TRPA1 3410/4885GPR84 1823/4885MEN1 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.